u/elin_lundgren

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.

fatigue plus low intake is usually just low intake

the injection-site soreness that arrives at week 37 out of nowhere is usually something else

Nothing in this thread is medical advice, including this comment. I am describing a mechanism, not telling anybody what to do about their own week.

write down when it starts and stops, the pattern is the useful part

That is preclinical work and the thread is treating it as a human finding.

Agreed. Slowing down at meals did more for my early fullness than everything I bought to fix it, which was embarrassing to discover.

Has anything else changed in the same window?

the food noise going quiet is the effect people came for, and early fullness is the toll for the first fortnight

receptor distribution is why the side effects are where they are

Is that from a human study or a preclinical model?

Which receptor arm are you attributing that to?

Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.

Severe or persistent abdominal pain sits outside the pattern this board can usefully discuss. The honest answer there is that it needs someone who can examine you.

Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.

Nobody warned me about muscle cramps and I would have liked the warning. It was not dangerous, it was just deeply unpleasant and completely unexpected.

Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.

Bought four different things to fix my early fullness. What actually worked was eating half as fast.

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

A symptom that begins the day after the shot and fades by day four tracks the exposure curve. One that appears at random in week 65 probably does not, and that is worth saying to a clinician rather than to us.

That study was in a rodent model. Worth stating, since the thread has been reading it as human data.

Which day of the week relative to the shot does it hit?

Kept a log purely because so few people are logging this one.

ines_ekstrom is right that the evidence base here is thin. Conclusions should be held loosely.

How long has it been going on for now?

fatigue plus low intake is usually just low intake

sulphur burps are unpleasant and they are not dangerous

Same pattern here. It settled at a stable dose without me doing anything clever.

read the combination arms separately from the monotherapy arms

the constipation that arrives at week 87 out of nowhere is usually something else

Constipation is mostly reduced intake plus reduced fluid, not a direct effect. That is why the boring fibre and water answer keeps working.

a rough fortnight at each step is normal, a rough three months is not

That symptom is not the one being described upthread. Two different things with similar names and the answers are not interchangeable.

A symptom that begins the day after the shot and fades by day four tracks the exposure curve. One that appears at random in week 89 probably does not, and that is worth saying to a clinician rather than to us.

Severe, or unpleasant? They are genuinely different questions and the answers diverge.

early fullness for the first eight days after each step, then nothing, every single time. Predictable enough that I started planning my week around it.

write down when it starts and stops, the pattern is the useful part

Hair shedding after significant weight loss is a telogen effect that follows the rate of loss. It is not specific to these compounds and it resolves.